Susceptibility to arbekacin of clinical strains of Pseudomonas aeruginosa isolated in the Tohoku area between 2003 and 2007

Shigeru Fujimura, Kazunori Gomi, Hidenari Takane, Yoshihisa Nakano, Katsuhiro Fuse, Toshiaki Kikuchi, Yutaka Tokue, Akira Watanabe

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)


We surveyed the susceptibility to ceftazidime, arbekacin(ABK), gentamycin(GM), and amikacin(AMK) of 1,348 strains of Pseudomonas aeruginosa isolated between 2003 and 2007 from patients hospitalized in the Tohoku area, Japan. Susceptibility was tested by the broth microdilution method using frozen plates. Metallo-β-lactamase (MBL) -producing P. aeruginosa was detected by the sodium mercaptoacetate(SMA) disc method, and PCR was used to detect the MBL type. Results of yearly susceptibility testing showed that the MIC50 and MIC90 of aminoglycoside antibiotics against 1.266 P. aeruginosa strains except for 64 MBL-producers and 18 non-MBL multidrug-resistant P. aeruginosa(MDRP) strains, between 2003 and 2007 were 2-4 μg/mL in ABK and GM, and 4 μg/mL, respectively. On the other hand, the range of MIC90 of ABK and GM were 8 to 16 μg/mL and those of AMK were 8 to 32 μg/mL. ABK was more effective than AMK, but MBL-producers and non-MBL MDRP were resistant to these 3 aminoglycoside antibiotics. P. aeruginosa and methicillin-resistant Staphylococcus aureus(MRSA) are frequently isolated as the cause of nosocomial pneumonia and wound infection. Mixed infection by these strains is also frequently encountered. ABK, which is an anti-MRSA drug, may prove effective against nosocomial infection by P. aeruginosa.

Original languageEnglish
Pages (from-to)91-96
Number of pages6
JournalJapanese Journal of Chemotherapy
Issue number2
Publication statusPublished - 2009 Mar


  • Arbekacin
  • Drug resistance
  • Multiple drug resistant Pseudomonas aeruginosa (MDRP)
  • Pseudomonas aeruginosa

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Susceptibility to arbekacin of clinical strains of Pseudomonas aeruginosa isolated in the Tohoku area between 2003 and 2007'. Together they form a unique fingerprint.

Cite this